Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Dalian University

Status and phase: Unknown; Phase 1

Conditions: Non-small Cell Lung Cancer

Treatments: Other: standard lung cancer treament; Biological: CIK cells with PD-1 blocking; Biological: CIK cells without PD-1 blocking

Study type: Interventional

Funder types: Other

Identifiers

NCT03282435

zsyy_zxsys2018-01

Details and patient eligibility

About

to evaluate the prognosis of non-small cell lung carcinoma patients under CIK cellular treatment with PD-1 blocking on top of the standard therapy

Enrollment: 30 estimated patients

Sex: All

Ages: 40 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• non-small cell lung cancer;
• more than 50% tumor tissues positive with PD-L1;
• EGFR and ALK wild type
• no other tumors

Exclusion criteria

• with systematic diseases shortening survival

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Factorial Assignment

Masking: Quadruple Blind

---

30 participants in 2 patient groups

CIK cells with PD-1 blocking

Experimental group

Description:

CIK cellular therapy with PD-1 blocking combined with standard lung cancer treatment

Treatment:

Biological: CIK cells with PD-1 blocking

Other: standard lung cancer treament

CIK cells without PD-1 blocking

Active Comparator group

Description:

CIK cellular therapy without PD-1 blocking combined with the same standard lung cancer treatment as the experimental group patients receive

Treatment:

Biological: CIK cells without PD-1 blocking

Other: standard lung cancer treament